Effects of acute pressure overload on prostacyclin release and myocardial blood flow in canine hearts: inhibition of prostacyclin synthesis with 15-hydroperoxy-eicosatetraenoic acid.
This study was undertaken to evaluate the effects of acute pressure overload on prostacyclin (PGI2) release and the influences of 15-hydroperoxy-eicosatetraenoic acid (15-HPETE), an inhibitor of PGI2 synthetase, and indomethacin, an inhibitor of cyclo-oxygenase, in canine hearts. Gradual stenosis of the ascending aorta was performed in 24 anesthetized open-chest dogs. The mongrel dogs were divided into three groups, which received indomethacin, 15-HPETE, and no drug. Changes in the hemodynamics, regional myocardial blood flow (MBF) by the method of H2 gas clearance, and plasma immunoreactive 6-keto-prostaglandin (PG) F1 alpha level in the descending aorta (AO) and great cardiac vein (GCV) were measured. Five minutes after aortic stenosis, the plasma immunoreactive 6-keto-PGF1 alpha level in the GCV and MBF increased from 162 +/- 23 to 289 +/- 37 pg/ml and from 87 +/- 5 to 107 +/- 8 ml/min/100 g, respectively, and the calculated coronary vascular resistance (CVR) decreased significantly from 0.93 +/- 0.08 to 0.77 +/- 0.08 mmHg/ml/min/100 g. These significant changes persisted thereafter. Continuous infusion of 15-HPETE (66 pg/kg/min) into the coronary artery simultaneously prevented significant changes in MBF and the plasma immunoreactive 6-keto-PGF1 alpha level in the GCV and CVR. Intravenous infusion of indomethacin (5 mg/kg), on the other hand, induced a significant decrease in the plasma immunoreactive 6-keto-PGF1 alpha level in both the GCV and AO; significant changes in MBF 5 to 15 min after aortic stenosis and CVR were not affected. From these results, it is suggested that PGI2 plays an important role in the regulation of coronary blood flow in canine hearts with acute pressure overload.(ABSTRACT TRUNCATED AT 250 WORDS)
Imaizumi
M
M
Ito
Y
Y
Ito
T
T
Ogawa
K
K
Satake
T
T
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000208:Acute Disease; D000818:Animals; D001024:Aortic Valve Stenosis / Q000097:blood / Q000503:physiopathology*; D001095:Arachidonic Acids / Q000494:pharmacology*; D001794:Blood Pressure; D003326:Coronary Circulation; D004285:Dogs; D011464:Epoprostenol / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism*; D005260:Female; D006439:Hemodynamics; D015289:Leukotrienes; D008054:Lipid Peroxides / Q000494:pharmacology*; D008297:Male; D014655:Vascular Resistance
D001095:Arachidonic Acids; D015289:Leukotrienes; D008054:Lipid Peroxides; D015121:6-Ketoprostaglandin F1 alpha; C025086:15-hydroperoxy-5,8,11,13-eicosatetraenoic acid; D011464:Epoprostenol